Role of the tumor suppressor KLF6 in prostate cancer

描述（由申请人提供）：前列腺癌（PCa）是男性癌症死亡的主要原因，诊断病例稳步增加。在美国，今年将有大约198，000人被确诊，32，000人死亡。因此，鉴定前列腺肿瘤发生、生长和转移扩散的致病基因和分子途径是改进诊断和预防及治疗策略的基本原理发展的迫切优先事项。我们证明，肿瘤抑制因子KLF 6，一个成员的Kruppel样家族的锌指转录因子，调节生长相关的信号转导途径，经常在人类前列腺癌失活。两条证据表明KLF 6状态可以定义PCa的易感性和长期结果。首先，在一项对3,400多名男性进行的多机构研究中，我们已经证明，无论家族病史如何，特定的种系KLF 6 SNP都会增加PCa的终生风险。该SNP增加KLF 6基因选择性剪接以产生生物活性的、促进生长的同种型KLF 6-SV 1，其增加肿瘤细胞增殖、侵袭和体内肿瘤生长。其次，多基因表达研究将KLF 6表达降低与肿瘤复发、临床结果差和化疗耐药性联系起来。因此，该提议的假设是野生型KLF 6的缺失和/或其可变剪接同种型KLF 6-SV 1的表达增加在PCa发展、进展和转移的谱中起中心作用。我们的目标是确定KLF 6和KLF 6-SV 1失调对肿瘤行为的临床病理学影响，并通过基因工程体内模型，确定这些生物学效应对PCa的遗传和蛋白质组学机制。因此，本提案的具体目的是：（1）确定KLF 6和KLF 6-SV 1表达改变在PCa发展和进展中的患病率和临床病理学效应;（2）研究靶向KLF 6和KLF 6-SV 1操纵对前列腺发育、肿瘤易感性和恶性转化的影响;（3）明确KLF 6-PCa相互作用组-KLF 6和KLF 6-SV 1蛋白相互作用在肿瘤发生和转移中的作用。

DESCRIPTION (provided by applicant): Prostate cancer (PCa) is a leading cause of cancer death in men and diagnosed cases steadily increase. In the U.S., approximately 198,000 men will be diagnosed and 32,000 will die this year. Therefore, identification of causative genes and molecular pathways underlying prostate tumor initiation, growth and metastatic spread represents an urgent priority for the rationale development of improved diagnostics and preventative and therapeutic strategies. We demonstrated that the tumor suppressor KLF6, a member of the Kruppel-like family of zinc finger transcription factors which regulate growth-related signal transduction pathways, is frequently inactivated in human PCa. Two lines of evidence now suggest that KLF6 status can both define PCa susceptibility and long-term outcome. First, in a multi-institutional study of over 3,400 men, we have shown that a specific germline KLF6 SNP, regardless of family history of disease, increases lifetime risk of PCa. This SNP increases KLF6 gene alternative splicing to yield a biologically active, growth- promoting isoform, KLF6-SV1, that increases tumor cell proliferation, invasion, and in vivo tumor growth. Second, multiple gene expression studies link decreased KLF6 expression with tumor recurrence, poor clinical outcomes and chemotherapeutic resistance. Therefore, the hypothesis of this proposal is that loss of wild type KLF6 and/or increased expression of its alternatively spliced isoform KLF6-SV1, play a central role in the spectrum of PCa development, progression and metastasis. Our goals are to identify the clinicopathologic impact of KLF6 and KLF6-SV1 dysregulation on tumor behaviour and through genetically engineered in vivo models, identify the genetic and proteomic mechanisms underlying these biologic effects on PCa. Therefore, the specific aims of this proposal are: (1) Define the prevalence and clinicopathologic effects of altered KLF6 and KLF6-SV1 expression in PCa development and progression; (2) Investigate the effects of targeted KLF6 and KLF6-SV1 manipulation on prostate development, tumor susceptibility and malignant transformation, and; (3) Define the "KLF6-PCa interactome" - KLF6 and KLF6-SV1 protein-protein interactions critical to tumorigenesis and metastasis.